期刊文献+

溴隐亭治疗肢端肥大症继发糖尿病与糖耐量异常报告 被引量:2

SECONDARY DIABETES AND IGT IN THE TREATMENT OF ACROMEGALY WITH BROMOCRIPTINE
下载PDF
导出
摘要 1983─1993年6月收治肢端肥大症28例中,糖耐量异常(IGT)5例占18.5%,糖尿病11例占39.28%,采用溴隐亭治疗5例IGT恢复正常,3例无临床症状,FBS8.8~15mmol/L治疗一月后FBS降至正常。4例有临床症状FBS15~16mmol/L,仅用溴隐亭7.5~15mg/日治疗,FBS除1例外均正常。4例FBS12.046~49.237mmol/L,尿糖++~+++,采用饮食控制并加用胰岛素24~96u/日,3例再加服优降糖2.5~7.5mg/日,疗效不佳,加用溴隐亭后获得较明显效果。认为肢端肥大症继发糖尿病,采用治疗Ⅰ型、Ⅱ型糖尿病的方法,均不能获得满意疗效,即使放疗后或手术加放疗后均一样,应首选溴隐亭治疗。 AbstractEleven cases of acromegaly withovert secondary diabetes were treated byBromocriptine.The IGT of 5 cases at 1 month after administration of Bromo-criptine returned to normal.the followup FBS level of 6 cases at 1 monthafter administration of Bromocriptine returned to normal from 8.8~15mmol/L before the treatment.5 cases whose FBS ranged from 12.046 to49.231 mmol/L and glucosunia from(++)to(+++)were treated with acombination of diet and Insuline with a dose 24-96U/day at begining,but nosignificant effects developed.So one among them was treated additionally withBromocriptine in dosage starting from 2.5mg and increasing gradually up to10mg per day,1 week later her FBS decreased from 12.046 mmol/L to 4.219mmol/L and glucosunia became negative.
出处 《云南医药》 CAS 1994年第3期170-173,共4页 Medicine and Pharmacy of Yunnan
  • 相关文献

同被引文献22

  • 1刘纪宁.溴隐亭的临床应用[J].实用内科杂志,1989,9(11):613-615. 被引量:3
  • 2朱宪彝.内科学内分泌腺疾病分册[M].天津:天津科学技术出版社,1979.14.
  • 3项坤三.溴隐亭对成年型糖尿病的作用[J].国外医学:内分泌学分册,1981,3:162-163.
  • 4Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes[J]. Diabetes Care, 2000, 23(8): 1154.
  • 5Kerr JL, Timpe EM, Petkewicz KA. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus[J]. Ann Pharmacother, 2010, 44(11): 1777-1785.
  • 6Gaziano JM, Cincotta AH, Vinik A, et al. Effect of bromocripfine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects[J]. JAHA, 2012, 1(5): e002279.
  • 7Cineotta AH, Meier AH, Cineotta JrM. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes[J]. Expert Opin Investig Drugs, 1999, 8(10): 1683-1707.
  • 8Mikhail N. Quick-release bromocriptine for treatment of type 2 diabetes[J]. Curr Drug Deliv, 2011, 8(5): 511-516.
  • 9Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters(Mesocricetus auratus)[J]. Metabolism, 1995, 44(10): 1349-1355.
  • 10Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes[J]. Diabetes Care, 2011, 34(6): 789-794.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部